170 related articles for article (PubMed ID: 35552764)
21. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
22. Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy.
Zhang H; Tang WL; Kheirolomoom A; Fite BZ; Wu B; Lau K; Baikoghli M; Raie MN; Tumbale SK; Foiret J; Ingham ES; Mahakian LM; Tam SM; Cheng RH; Borowsky AD; Ferrara KW
J Control Release; 2021 Feb; 330():1080-1094. PubMed ID: 33189786
[TBL] [Abstract][Full Text] [Related]
23. Multifunctional nanoparticles based on a polymeric copper chelator for combination treatment of metastatic breast cancer.
Zhou P; Qin J; Zhou C; Wan G; Liu Y; Zhang M; Yang X; Zhang N; Wang Y
Biomaterials; 2019 Mar; 195():86-99. PubMed ID: 30623789
[TBL] [Abstract][Full Text] [Related]
24. T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles.
Turco V; Pfleiderer K; Hunger J; Horvat NK; Karimian-Jazi K; Schregel K; Fischer M; Brugnara G; Jähne K; Sturm V; Streibel Y; Nguyen D; Altamura S; Agardy DA; Soni SS; Alsasa A; Bunse T; Schlesner M; Muckenthaler MU; Weissleder R; Wick W; Heiland S; Vollmuth P; Bendszus M; Rodell CB; Breckwoldt MO; Platten M
Nat Commun; 2023 Feb; 14(1):771. PubMed ID: 36774352
[TBL] [Abstract][Full Text] [Related]
25. Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular Carcinoma
Tian Z; Hong B; Chen J; Tang Z
Front Oncol; 2022; 12():891724. PubMed ID: 35719978
[TBL] [Abstract][Full Text] [Related]
26. A sugar modified amphiphilic cationic nano-adjuvant ceased tumor immune suppression and rejuvenated peptide vaccine induced antitumor immunity in cervical cancer.
Mohapatra A; Rajendrakumar SK; Cherukula K; Park MS; Padmanaban S; Vasukuty A; Mohanty A; Lee JY; Bae WK; Park IK
Biomater Sci; 2023 Feb; 11(5):1853-1866. PubMed ID: 36655902
[TBL] [Abstract][Full Text] [Related]
27. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.
Kim H; Khanna V; Kucaba TA; Zhang W; Sehgal D; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2020 Jun; 17(6):2109-2124. PubMed ID: 32383885
[TBL] [Abstract][Full Text] [Related]
28. Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy.
Rodell CB; Ahmed MS; Garris CS; Pittet MJ; Weissleder R
Theranostics; 2019; 9(26):8426-8436. PubMed ID: 31879528
[TBL] [Abstract][Full Text] [Related]
29. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors.
Bahmani B; Gong H; Luk BT; Haushalter KJ; DeTeresa E; Previti M; Zhou J; Gao W; Bui JD; Zhang L; Fang RH; Zhang J
Nat Commun; 2021 Mar; 12(1):1999. PubMed ID: 33790276
[TBL] [Abstract][Full Text] [Related]
30. Heat-Confined Tumor-Docking Reversible Thermogel Potentiates Systemic Antitumor Immune Response During Near-Infrared Photothermal Ablation in Triple-Negative Breast Cancer.
Revuri V; Rajendrakumar SK; Park MS; Mohapatra A; Uthaman S; Mondal J; Bae WK; Park IK; Lee YK
Adv Healthc Mater; 2021 Nov; 10(21):e2100907. PubMed ID: 34541833
[TBL] [Abstract][Full Text] [Related]
31. Pre-activation with TLR7 in combination with thioridazine and loratadine promotes tumoricidal T-cell activity in colorectal cancer.
Lin X; Zhang J; Wang X; Lin G; Chen T
Anticancer Drugs; 2020 Nov; 31(10):989-996. PubMed ID: 32694422
[TBL] [Abstract][Full Text] [Related]
32. Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses.
Nuhn L; De Koker S; Van Lint S; Zhong Z; Catani JP; Combes F; Deswarte K; Li Y; Lambrecht BN; Lienenklaus S; Sanders NN; David SA; Tavernier J; De Geest BG
Adv Mater; 2018 Nov; 30(45):e1803397. PubMed ID: 30276880
[TBL] [Abstract][Full Text] [Related]
33. Exosome-mediated delivery of transforming growth factor-β receptor 1 kinase inhibitors and toll-like receptor 7/8 agonists for combination therapy of tumors.
Lee JH; Song J; Kim IG; You G; Kim H; Ahn JH; Mok H
Acta Biomater; 2022 Mar; 141():354-363. PubMed ID: 35007784
[TBL] [Abstract][Full Text] [Related]
34. Antitumor Activity of TLR7 Is Potentiated by CD200R Antibody Leading to Changes in the Tumor Microenvironment.
Pilch Z; Tonecka K; Braniewska A; Sas Z; Skorzynski M; Boon L; Golab J; Meyaard L; Rygiel TP
Cancer Immunol Res; 2018 Aug; 6(8):930-940. PubMed ID: 30021725
[TBL] [Abstract][Full Text] [Related]
35. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.
Adlard AL; Dovedi SJ; Telfer BA; Koga-Yamakawa E; Pollard C; Honeychurch J; Illidge TM; Murata M; Robinson DT; Jewsbury PJ; Wilkinson RW; Stratford IJ
Int J Cancer; 2014 Aug; 135(4):820-9. PubMed ID: 24390981
[TBL] [Abstract][Full Text] [Related]
36. IL-27 Is Essential for Suppression of Experimental Allergic Asthma by the TLR7/8 Agonist R848 (Resiquimod).
Jirmo AC; Daluege K; Happle C; Albrecht M; Dittrich AM; Busse M; Habener A; Skuljec J; Hansen G
J Immunol; 2016 Dec; 197(11):4219-4227. PubMed ID: 27799314
[TBL] [Abstract][Full Text] [Related]
37. Liposomal Resiquimod for Enhanced Immunotherapy of Peritoneal Metastases of Colorectal Cancer.
Pauli G; Chao PH; Qin Z; Böttger R; Lee SE; Li SD
Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683992
[TBL] [Abstract][Full Text] [Related]
38. The TLR7 ligand R848 prevents mouse graft-
Gaignage M; Marillier RG; Cochez PM; Dumoutier L; Uyttenhove C; Coutelier JP; Van Snick J
Haematologica; 2019 Feb; 104(2):392-402. PubMed ID: 30213828
[TBL] [Abstract][Full Text] [Related]
39. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
[TBL] [Abstract][Full Text] [Related]
40. TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function.
Spinetti T; Spagnuolo L; Mottas I; Secondini C; Treinies M; Rüegg C; Hotz C; Bourquin C
Oncoimmunology; 2016; 5(11):e1230578. PubMed ID: 27999739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
